METAGENOMI, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.8 USD | +3.98% |
|
0.00% | 0.00% |
| May. 07 | HC Wainwright Starts Metagenomi With Buy Rating, $10 Price Target | MT |
| May. 03 | North American Morning Briefing : Apple, Amgen -2- | DJ |
Valuation
| Fiscal Period: December | 2024 | 2025 | 2026 |
|---|---|---|---|
| Capitalization 1 | 140.3 | - | - |
| Enterprise Value (EV) 1 | 140.3 | 140.3 | 140.3 |
| P/E ratio | -1.88 x | -2.21 x | -2.71 x |
| Yield | - | - | - |
| Capitalization / Revenue | 3.85 x | 3.82 x | 1.72 x |
| EV / Revenue | 3.85 x | 3.82 x | 1.72 x |
| EV / EBITDA | -1.66 x | -1.2 x | - |
| EV / FCF | -3.42 x | -1.53 x | -2.41 x |
| FCF Yield | -29.2% | -65.4% | -41.4% |
| Price to Book | - | - | - |
| Nbr of stocks (in thousands) | 21,451 | - | - |
| Reference price 2 | 6.540 | 6.540 | 6.540 |
| Announcement Date | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | - | 44.76 | 36.45 | 36.74 | 81.7 |
| EBITDA 1 | - | -74.28 | -84.3 | -117.4 | - |
| EBIT 1 | - | -78.49 | -123 | -138.3 | -154.6 |
| Operating Margin | - | -175.38% | -337.49% | -376.42% | -189.18% |
| Earnings before Tax (EBT) 1 | - | -60.23 | -105.2 | -136.3 | -154.6 |
| Net income 1 | -43.59 | -68.26 | -116.5 | -133 | -158.6 |
| Net margin | - | -152.5% | -319.67% | -362.06% | -194.09% |
| EPS 2 | -7.340 | -20.05 | -3.475 | -2.959 | -2.413 |
| Free Cash Flow 1 | - | -101.2 | -41 | -91.8 | -58.1 |
| FCF margin | - | -226.17% | -112.49% | -249.88% | -71.11% |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 8/3/23 | 3/27/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|
| Net sales 1 | 12.4 | 11.16 | 10.98 | 9.333 | 9.333 | 11 |
| EBITDA | - | - | - | - | - | - |
| EBIT 1 | -20.2 | -29.03 | -27 | -32.62 | -33.2 | -30.45 |
| Operating Margin | -162.88% | -260.17% | -245.99% | -349.46% | -355.75% | -276.82% |
| Earnings before Tax (EBT) 1 | -16.57 | -25.15 | -23.55 | -28.75 | -29.48 | - |
| Net income 1 | -19.29 | -25.15 | -24.04 | -28.32 | -29.02 | -27.86 |
| Net margin | -155.61% | -225.36% | -219.08% | -303.43% | -310.91% | -253.29% |
| EPS 2 | -5.670 | -1.190 | -0.6001 | -0.7785 | -0.7992 | -0.7400 |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 3/27/24 | 5/14/24 | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - |
| Net Cash position | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow 1 | - | -101 | -41 | -91.8 | -58.1 |
| ROE (net income / shareholders' equity) | - | - | -25.8% | -31.9% | - |
| ROA (Net income/ Total Assets) | - | -17.5% | -17.9% | -22.5% | - |
| Assets 1 | - | 389.6 | 649.6 | 590.3 | - |
| Book Value Per Share | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - |
| Capex 1 | - | 9.81 | 15 | 14 | 14 |
| Capex / Sales | - | 21.93% | 41.16% | 38.13% | 17.14% |
| Announcement Date | 8/3/23 | 3/27/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
6.8
USD
Average target price
16.83
USD
Spread / Average Target
+147.55%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| 0.00% | 245M | |
| +29.77% | 49.18B | |
| +1.00% | 42.11B | |
| +50.47% | 40.37B | |
| -5.26% | 28.85B | |
| +13.68% | 26.09B | |
| -22.99% | 18.71B | |
| +8.22% | 13.26B | |
| +32.41% | 12.32B | |
| -1.62% | 11.99B |
- Stock Market
- Equities
- MGX Stock
- Financials Metagenomi, Inc.
